ClinicalTrials.gg
CompletedNCT01257048Updated Sep 3, 2012

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

An Early Phase 1 interventional study of Formoterol Turbuhaler and Budesonide/Formoterol Turbuhaler in COPD Method Evaluation and Chronic Obstructive Pulmonary Disease Method Evaluation, sponsored by AstraZeneca. Completed at 2 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.

Sponsored by AstraZeneca · Early Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
34th of 43
34 · median 99
Started
2011
with 1 other
Phase 1
6 of 43
none open now
Registered
11th of 43
by date
Lead sponsor
10 of 43
AstraZeneca

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 34th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 1, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the sensitivity of a new oxygen enhanced magnetic resonance imaging (OE-MRI) method in detecting changes in the lungs of patients with moderate to severe chronic obstructive pulmonary disease (COPD) following treatment with either Oxis Turbuhaler or Symbicort Turbuhaler.

03

Conditions studied

  • COPD Method Evaluation
  • Chronic Obstructive Pulmonary Disease Method Evaluation

Keywords

  • Oxygen enhanced magnetic resonance imaging
  • chronic obstructive pulmonary disease
  • method evaluation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 40 years
  • Male and female
  • Clinical diagnosis of moderate to severe according GOLD guidelines
  • Current or ex smoker with a smoking history equivalent to at least 20 cigarettes smoked per day for 10 years
  • A Modified Medical Research Council (MMRC) dyspnoea scale score of ≥2.
  • /FVC \< 0.7 (post-bronchodilator)
  • FEV1 > 40 % PN and \< 70 % PN (post-bronchodilator)

Clinical Study Protocol Local Amendment affects UK:

  • FEV1 > 30 % PN and \< 80 % PN (post-bronchodilator)

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of asthma according to GINA guidelines
  • Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable measures as judged by the investigator
  • Significant upper or lower respiratory tract infection not fully recovered in the 4 weeks prior to visit 1
  • Participation in or scheduled for an intensive rehabilitation program
  • Claustrophobia, pacemaker, clips within the brain, previous brain or heart surgery, history of metal in the eye or other MRI such as obesity or inability to stay in the supine position for 60 minutes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Placebo comparator
    1

    Single Dose evaluation placebo (V5)

    Drug: Formoterol Turbuhaler

  • Active comparator
    2

    Single Dose evaluation formoterol (V5)

    Drug: Budesonide/Formoterol Turbuhaler · Drug: Formoterol Turbuhaler

Interventions

06

What researchers measure

Primary outcomes

  1. Oxygen enhanced MRI V4

    Oxygen enhanced magnetic resonance imaging (OE-MRI) parameters

    Time frame: Visit 4

  2. Oxygen enhanced MRI V5

    Oxygen enhanced MRI parameters

    Time frame: Visit 5

  3. Oxygen enhanced MRI V7

    Oxygen enhanced MRI parameters

    Time frame: Visit 7

Secondary outcomes

  1. Transferability of OE-MRI technique

    Transferability of OE-MRI technique to a second centre

    Time frame: 10 months

  2. OE-MRI variables

    Relationship with OE-MRI variables and change in lung function

    Time frame: patients will fill in a patient diary at home between visit 2 and 7

  3. Impulse oscillometry parameters V2

    Impulse oscillometry parameters

    Time frame: Visit 2

  4. Impulse oscillometry parameters V4

    Impulse oscillometry parameters

    Time frame: Visit 4

  5. Impulse oscillometry parameters V5

    Impulse oscillometry parameters

    Time frame: Visit 5

  6. Impulse oscillometry parameters V7

    Impulse oscillometry parameters

    Time frame: Visit 7

07

Study locations

2 sites
  • Research Site
    Lund, Sweden
  • Research Site
    Manchester, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2010
First posted
Dec 9, 2010
Start
Aug 2011
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Sep 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01257048
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 9, 2010
Start date
Aug 2011
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Sep 3, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion